o-Anisidine
RTECS #
BZ5410000
CAS #
Updated
December 2018
Molecular Weight
123.17
Molecular Formula
C7H9NO
Synonyms
1-Amino-2-methoxybenzene
2-Aminoanisole
2-Anisidine
2-Methoxy-1-aminobenzene
2-Methoxyaniline
2-Methoxybenzenamine
2-Methoxyphenylamine
Benzenamine, 2-methoxy- (9CI)
o-Aminoanisole
o-Anisidine (ACGIH:OSHA)
o-Anisylamine
o-Methoxyaniline
o-Methoxyphenylamine
2-Aminoanisole
2-Anisidine
2-Methoxy-1-aminobenzene
2-Methoxyaniline
2-Methoxybenzenamine
2-Methoxyphenylamine
Benzenamine, 2-methoxy- (9CI)
o-Aminoanisole
o-Anisidine (ACGIH:OSHA)
o-Anisylamine
o-Methoxyaniline
o-Methoxyphenylamine
Mutation Data and Reference
System Test | Route/Organism/Tissue | Dose | Reference |
---|---|---|---|
Cytogenetic Analysis | ovary/hamster | 1200 mg/L | EMMUEG 10(Suppl 10),1,1987 |
DNA Damage | oral/rat | 1800 mg/kg/3D- intermittent | MUREAV 786-788,172,2015 |
DNA Damage | lymphocyte/mouse | 1250 µmol/L | MUREAV 203,155,1988 |
DNA Damage | oral/mouse | 690 mg/kg | MUREAV 412,155,1998 |
DNA inhibition | oral/mouse | 200 mg/kg | MUREAV 46,305,1977 |
DNA repair | /Escherichia coli | 31600 µmol/L | MUREAV 272,145,1992 |
gene conversion and mitotic recombination | /Drosophila melanogaster | 1 mmol/L | MUREAV 514,193,2002 |
host-mediated assay | Escherichia coli/mouse | 310 mg/kg | MUREAV 272,161,1992 |
mutation in mammalian somatic cells | lymphocyte/mouse | 2 mmol/L | MUTAEX 3,193,1988 |
mutation in microorganisms | /Salmonella typhimurium | 333 µg/plate (-enzymatic activation step) | IMEMDT 27,63,1982 |
mutation in microorganisms | lymphocyte/mouse | 1 mmol/L (+enzymatic activation step) | MUTAEX 3,193,1988 |
sister chromatid exchange | ovary/hamster | 38 mg/L | EMMUEG 10(Suppl 10),1,1987 |
Acute Toxicity Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
In Vitro/Human, leukemia cells | Inhibitor Concentration (50 percent kill): 13.2 mmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 40,153,2017 |
In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 12.5 mmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 40,153,2017 |
In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 0.5 mmol/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 40,153,2017 |
In Vitro/Human, liver tumor | Inhibitor Concentration Low: 6.3 mmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 40,153,2017 |
In Vitro/Human, liver tumor | Inhibitor Concentration Low: 5 mmol/L/3H | In Vitro Toxicity Studies: Other assays | TIVIEQ 40,153,2017 |
In Vitro/Human, liver tumor | Inhibitor Concentration Low: 1.6 mmol/L/3H | Biochemical: Metabolism (intermediary): Effect on mitochondrial function | TIVIEQ 40,153,2017 |
In Vitro/Human, liver tumor | Inhibitor Concentration Low: 1.5 mmol/L/24H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 40,153,2017 |
In Vitro/Human, liver tumor | Inhibitor Concentration Low: 0.5 mmol/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 40,153,2017 |
In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 6.9 mmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 40,153,2017 |
In Vitro/Mouse, liver | Inhibitor Concentration Low: 6.3 mmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 40,153,2017 |
In Vitro/Mouse, liver | Inhibitor Concentration (50 percent kill): 13 mmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 40,153,2017 |
In Vitro/Mouse, liver | Inhibitor Concentration Low: 2.5 mmol/L/3H | In Vitro Toxicity Studies: Other assays | TIVIEQ 40,153,2017 |
oral/mouse | lethal dose (50 percent kill): 1400 mg/kg | Kidney, Ureter, and Bladder: Other changes Blood: Normocytic anemia Blood: Other changes | IMEMDT 27,63,1982 |
oral/rabbit | lethal dose (50 percent kill): 870 mg/kg | Kidney, Ureter, and Bladder: Other changes Blood: Normocytic anemia Blood: Other changes | IMEMDT 27,63,1982 |
oral/rat | lethal dose (50 percent kill): 1150 mg/kg | TLSMA6 128,14,1979 | |
oral/wild bird | lethal dose (50 percent kill): 422 mg/kg | AECTCV 12,355,1983 |
Reviews
Organization | Standard | Reference |
---|---|---|
American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 0.5 mg/m3 (skin) | DTLVS* TLV/BEI,2013 |
American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Confirmed animal carcinogen | DTLVS* TLV/BEI,2013 |
International Agency for Research on Cancer (IARC) | Cancer Review:Animal Sufficient Evidence | IMEMDT 73,49,1999 |
International Agency for Research on Cancer (IARC) | Cancer Review:Human No Adequate Data | IMEMDT 27,63,1982 |
International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 73,49,1999 |
International Agency for Research on Cancer (IARC) | Cancer Review:Group 2B | IMEMDT 73,49,1999 |
TOXICOLOGY REVIEW | ENTOX* -,104,2005 | |
TOXICOLOGY REVIEW | MUREAV 752,99,2013 | |
TOXICOLOGY REVIEW | MUREAV 786-788,14,2015 | |
TOXICOLOGY REVIEW | MUREAV 786-788,182,2015 | |
TOXICOLOGY REVIEW | RTOPDW 55,52,2009 |
Standards and Regulations
Organization | Standard | Reference |
---|---|---|
Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 0.1 ppm (0.5 mg/m3) (skin) | DTLWS* 3,10,1973 |
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
Occupational Exposure Limit-AUSTRALIA | time-weighted average 0.1 ppm (0.5 mg/m3), JAN1993 | |
Occupational Exposure Limit-AUSTRIA | TRK-TMW 0.1 ppm (0.5 mg/m3);KZW 0.2 ppm (1 mg/m3), skin, 2007 | |
Occupational Exposure Limit-BELGIUM | time-weighted average 0.1 ppm (0.5 mg/m3), Skin, MAR2002 | |
Occupational Exposure Limit-DENMARK | time-weighted average 0.1 ppm (0.5 mg/m3), skin, carc, MAY2011 | |
Occupational Exposure Limit-FINLAND | time-weighted average 0.1 ppm (0.5 mg/m3), short term exposure limit 0.3 ppm (1.5 mg/m3), skin, NOV2011 | |
Occupational Exposure Limit-FRANCE | VME 0.1 ppm (0.5 mg/m3), Skin, C2 Carcinogen, FEB2006 | |
Occupational Exposure Limit-HUNGARY | ceiling concentration 0.5 mg/m3, Carcinogen, SEP2000 | |
Occupational Exposure Limit-ICELAND | time-weighted average 0.1 ppm (0.5 mg/m3), carc, skin, NOV2011 | |
Occupational Exposure Limit-INDIA | time-weighted average 0.1 ppm (0.5 mg/m3), Skin, JAN1993 | |
Occupational Exposure Limit-JAPAN | Occupational Exposure Limit 0.1 ppm (0.5 mg/m3), skin, 2B carc, MAY2012 | |
Occupational Exposure Limit-KOREA | time-weighted average 0.5 mg/m3, skin, 2006 | |
Occupational Exposure Limit-MEXICO | time-weighted average 0.1 ppm (0.5 mg/m3) (skin), 2004 | |
Occupational Exposure Limit-NEW ZEALAND | time-weighted average 0.1 ppm (0.5 mg/m3), skin, JAN2002 | |
Occupational Exposure Limit-NORWAY | time-weighted average 0.1 ppm (0.5 mg/m3), JAN1999 | |
Occupational Exposure Limit-PERU | time-weighted average 0.1 ppm (0.5 mg/m3), JUL2005 | |
Occupational Exposure Limit-POLAND | MAC(time-weighted average) 0.5 mg/m3, MAC(short term exposure limit) 1 mg/m3, JAN1999 | |
Occupational Exposure Limit-RUSSIA | short term exposure limit 1 mg/m3, Skin, JUN2003 | |
Occupational Exposure Limit-SWITZERLAND | MAK-week 0.1 ppm (0.5 mg/m3), carc 2, skin, JAN2011 | |
Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 0.5 mg/m3, Skin, JAN1993 | |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 0.5 mg/m3 (skin) | CFRGBR 29,1926.55,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 0.5 mg/m3 (skin) | CFRGBR 41,50-204.50,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 0.5 mg/m3 (skin) | CFRGBR 29,1910.1000,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 0.5 mg/m3 (skin) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
Organization | Standard | Reference |
---|---|---|
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO o-ANISIDINE-air | 10H Carcinogen time-weighted average 0.5 mg/m3 (Sk) | NIOSH* DHHS #92-100,1992 |
National Occupational Exposure Survey 1983 | Hazard Code X8302; Number of Industries 1; Total Number of Facilities 50; Number of Occupations 3; Total Number of Employees Exposed 705 |
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health